HC Wainwright set a $5.00 target price on STRATA Skin Sciences (NASDAQ:SSKN) in a research report report published on Monday morning, Stock Target Advisor reports. The firm currently has a buy rating on the medical device company’s stock.
Other analysts also recently issued research reports about the company. Zacks Investment Research upgraded York Water from a sell rating to a hold rating in a research note on Saturday, June 1st. Northland Securities set a $5.00 price target on Communications Systems and gave the stock a buy rating in a research report on Tuesday, May 14th. Finally, ValuEngine downgraded Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. STRATA Skin Sciences has a consensus rating of Buy and an average price target of $4.92.
Shares of SSKN traded down $0.05 during mid-day trading on Monday, reaching $2.45. The company had a trading volume of 34,813 shares, compared to its average volume of 62,234. STRATA Skin Sciences has a 52-week low of $1.76 and a 52-week high of $3.88. The company has a 50 day moving average price of $2.27.
A number of hedge funds have recently modified their holdings of SSKN. Meitav Dash Investments Ltd. boosted its position in STRATA Skin Sciences by 12.8% in the 1st quarter. Meitav Dash Investments Ltd. now owns 807,234 shares of the medical device company’s stock valued at $2,314,000 after buying an additional 91,418 shares during the last quarter. Virtu Financial LLC purchased a new position in STRATA Skin Sciences in the 1st quarter valued at about $39,000. Nantahala Capital Management LLC boosted its position in STRATA Skin Sciences by 8.2% in the 4th quarter. Nantahala Capital Management LLC now owns 2,768,001 shares of the medical device company’s stock valued at $7,197,000 after buying an additional 209,110 shares during the last quarter. Northern Trust Corp purchased a new position in STRATA Skin Sciences in the 4th quarter valued at about $36,000. Finally, Acadian Asset Management LLC boosted its position in STRATA Skin Sciences by 79.3% in the 4th quarter. Acadian Asset Management LLC now owns 32,568 shares of the medical device company’s stock valued at $85,000 after buying an additional 14,408 shares during the last quarter. Institutional investors own 30.96% of the company’s stock.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.